Journal
CURRENT MEDICINAL CHEMISTRY
Volume 30, Issue 21, Pages 2357-2395Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867329666220615124412
Keywords
Selenium; mood; neurodegeneration; pharmacology; neuroprotection; therapeutic agents
Ask authors/readers for more resources
This review summarizes recent preclinical studies on organoselenium compounds as therapeutic agents for the treatment of mental and neurodegenerative diseases. Diaryl diselenides, Ebselen-derivatives, and Se-containing heterocycles are identified as the most representative organoselenium molecules. The review aims to provide disease-oriented information that can be useful for the development of novel bioactive molecules with potential clinical viability.
Neurodegenerative and mental disorders are a public health burden with pharmacological treatments of limited efficacy. Organoselenium compounds are receiving great attention in medicinal chemistry mainly because of their antioxidant and immunomodulatory activities, with a multi-target profile that can favor the treatment of multifactorial diseases. Therefore, the purpose of this review is to discuss recent preclinical studies about organoselenium compounds as therapeutic agents for the management of mental (e.g., depression, anxiety, bipolar disorder, and schizophrenia) and neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis). We have summarized around 70 peer-reviewed articles from 2016 to the present that used in silico, in vitro, and/or in vivo approaches to assess the neuropharmacology of selenium-containing compounds. Among the diversity of organoselenium molecules investigated in the last five years, diaryl diselenides, Ebselen-derivatives, and Se-containing heterocycles are the most representative. Ultimately, this review is expected to provide disease-oriented information regarding the neuropharmacology of organoselenium compounds that can be useful for the design, synthesis, and pharmacological characterization of novel bioactive molecules that can potentially be clinically viable candidates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available